A stable intestinal microflora plays a vital role in human health. Normal intestinal microflora performs a number of functions: it protects the body from pathogenic microbes, neutralizes toxins, stimulates the immune system, participates in the digestive process, ensures the synthesis and absorption of certain vitamins and minerals, regulates intestinal motility, normalizes peristalsis, regulates appetite, and more.

 

In addition to beneficial bacteria, the intestines are also home to opportunistic microorganisms. While these microorganisms remain undetected in healthy individuals, they can begin to proliferate when the body's defenses are weakened. This leads to digestive problems, general intoxication, and, over time, inflammation of the intestinal mucosa. A condition in which potentially harmful bacteria predominate in the intestines is called dysbiosis.

 

Dysbacteriosis can develop as a result of antibiotic use, intestinal infections, gastrointestinal diseases (gastritis, peptic ulcers, pancreatitis), low dietary fiber intake, and weakened immune systems. While microflora can contribute to the development of digestive diseases, any adverse changes in the body alter the composition and properties of the microflora.

 

Dysbacteriosis can cause bloating and abdominal pain, bad breath, diarrhea or, conversely, constipation, general malaise, loss of appetite, headache, and allergic reactions.

 

To correct intestinal dysbiotic imbalances, probiotics containing live cultures of lacto- and bifidobacteria, normal intestinal inhabitants, are usually prescribed. However, this may not be sufficient for the treatment of dysbacteriosis, especially chronic and long-term ones. To eliminate opportunistic microflora, the use of appropriate bacteriophages is advisable. Phage preparations are highly specific – they destroy only certain bacteria without affecting beneficial microflora. Furthermore, the risk of pathogenic bacteria developing resistance to them is minimal. Due to their high safety, bacteriophages are approved for use in children (see instructions). The use of bacteriophages stimulates specific and nonspecific immune factors, which is particularly effective in the treatment of chronic inflammatory diseases associated with immunosuppression.

 

Intestifag® or Pyofag® are used orally and rectally for dysbacteriosis. The medication is taken orally at the appropriate dose three times daily, one hour before meals, for 7-20 days. Bacteriophage can also be administered rectally as an enema – the appropriate dose administered once daily after a bowel movement, instead of once orally.

 

For prophylactic purposes, bacteriophage is taken orally at an age-appropriate dose once daily, one hour before meals. The duration of the course depends on the epidemic situation.

 

For age-specific dosages of the drug, see the Instructions for medical use of the medicinal product Intestifag® and the Instructions for medical use of the medicinal product Pyofag®.

 

 

Download the Instructions for medical use of the medicinal product Intestifag®

Download the instructions for medical use of the medicinal product Pyofag®

 

Intestifag® R.S. No. UA/15970/01/01. Approved by Order of the Ministry of Health of Ukraine No. 478 dated April 28, 2017.
Pyofag® R.S. No. UA/15974/01/01. Approved by Order of the Ministry of Health of Ukraine No. 478 dated April 28, 2017.

 

Information about this medication is provided for informational purposes only and should not be used as a guide to self-medication. Only a physician can prescribe this medication, as well as determine the dosage and method of administration.